Akshaya Keerti, International Council Deputy Director at Federation of Medical Students Association (FMSA), shared on LinkedIn:
“GLP-1 Receptor Agonists and Cancer Risk: A Quick Take for Oncologists
GLP-1 RAs like semaglutide and liraglutide are transforming obesity care — but what do they mean for cancer risk?
- Obesity drives at least 13 cancer types, including breast, colorectal, and endometrial.
- GLP-1 RAs reduce weight, inflammation, and insulin resistance — key cancer risk factors.
- Concerns? Pancreatic and thyroid cancer signals remain inconclusive in human data.
- Promise? Early evidence hints at lower GI and breast cancer incidence, but long-term studies are still needed.
As doctors, we must stay informed on how metabolic therapies may shift the cancer landscape.
Full breakdown here.”